Floatz logo

Gefetinib

EGFR

Shenzhen People's HospitalPhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

3 Active assets in the EGFR cohort.

Asset / SponsorPhaseRating
Osimertinib
Jianxing He
Phase 2CCC
Cyclophosphamide
Vir Biotechnology, Inc.
Phase 1CC
Epirubicin
Vir Biotechnology, Inc.
Phase 1CC

Same molecule, other indications

Gefetinib is also rated in:

central nervous system neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
gliosarcomaDormant
BB
Indicative ·
71 / 100
View asset →
lung adenocarcinoma in situDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →